Emily Chan
Executive Medical Director, Global Development Lead Amgen Inc.
Seminars
Tuesday 16th September 2025
Roundtable Discussion: Untangling the Regulatory Landscape Surrounding Combination Therapies to Accelerate More Innovative Treatments Towards the Patients in Need
3:15 pm
- Uncovering preclinical data and safety assessments required for combining a RAS inhibitor with another approved or unapproved drug
- How to overcome the regulatory hurdles associated with combining two unapproved drugs?
- Project Optimus: How much data is needed before dose selection for phase 3?
Tuesday 16th September 2025
Continuing Sotorasib Development by Uncovering Synergistic Combination Strategies to Treat Mutated Colorectal Cancer
3:45 pm
- Generating data in a 4% world: Doing more with less
- Highlighting considerations for design of pivotal phase 3 trial
- Uncovering a robust path to achieve regulatory approval
